According to the World Health Organization (WHO), lenacapavir offers a highly effective, long-acting alternative to daily ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating-and possibly even ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating—and possibly even ...

Attributing the rise in infections to increased testing, health officials said around 23 percent of those potentially living with HIV remain unaware of their health status.

Infectious disease experts have hailed a move that will see a highly effective HIV prevention drug be sold at just 40 dollars ...

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the most undervalued NASDAQ stocks to buy now. Citing momentum in Gilead ...

The slashing of foreign aid and closure of HIV programmes earlier this year is continuing to impact people living with HIV, writes Nick Ferris in Nairobi, causing serious damage to long-term efforts t ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions of a new and ...

Knowing how to leverage these technologies means we can help set the new standard and inform the next evolution of HIV care.

Uganda is one of the countries that's greatly affected by the reduction of U.S. foreign aid. Here's how the health care system is responding — with trepidation, innovation and resilience.

An old research report turned up in the headlines last month and left South Africans worried about our water systems. Bhekisisa joined up with Africa Check to find out how good research got ...